160 related articles for article (PubMed ID: 23934016)
1. Plasma osteopontin concentrations in patients with cutaneous melanoma.
Filia A; Elliott F; Wind T; Field S; Davies J; Kukalizch K; Randerson-Moor J; Harland M; Bishop DT; Banks RE; Newton-Bishop JA
Oncol Rep; 2013 Oct; 30(4):1575-80. PubMed ID: 23934016
[TBL] [Abstract][Full Text] [Related]
2. Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study.
Kadkol SS; Lin AY; Barak V; Kalickman I; Leach L; Valyi-Nagy K; Majumdar D; Setty S; Maniotis AJ; Folberg R; Pe'er J
Invest Ophthalmol Vis Sci; 2006 Mar; 47(3):802-6. PubMed ID: 16505010
[TBL] [Abstract][Full Text] [Related]
3. The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma.
Zhang H; Ye QH; Ren N; Zhao L; Wang YF; Wu X; Sun HC; Wang L; Zhang BH; Liu YK; Tang ZY; Qin LX
J Cancer Res Clin Oncol; 2006 Nov; 132(11):709-17. PubMed ID: 16786357
[TBL] [Abstract][Full Text] [Related]
4. High GDF-15 Serum Levels Independently Correlate with Poorer Overall Survival of Patients with Tumor-Free Stage III and Unresectable Stage IV Melanoma.
Weide B; Schäfer T; Martens A; Kuzkina A; Uder L; Noor S; Garbe C; Harter PN; Mittelbronn M; Wischhusen J
J Invest Dermatol; 2016 Dec; 136(12):2444-2452. PubMed ID: 27705749
[TBL] [Abstract][Full Text] [Related]
5. NF‑κB inhibition is associated with OPN/MMP‑9 downregulation in cutaneous melanoma.
Guarneri C; Bevelacqua V; Polesel J; Falzone L; Cannavò PS; Spandidos DA; Malaponte G; Libra M
Oncol Rep; 2017 Feb; 37(2):737-746. PubMed ID: 28075446
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of osteopontin expression in cervical cancer.
Cho H; Hong SW; Oh YJ; Kim MA; Kang ES; Lee JM; Kim SW; Kim SH; Kim JH; Kim YT; Lee K
J Cancer Res Clin Oncol; 2008 Aug; 134(8):909-17. PubMed ID: 18210151
[TBL] [Abstract][Full Text] [Related]
7. S100 protein serum levels in cutaneous malignant melanoma.
Seregni E; Massaron S; Martinetti A; Illeni MT; Rovini D; Belli F; Agresti R; Greco M; Cascinelli N; Bombardieri E
Oncol Rep; 1998; 5(3):601-4. PubMed ID: 9538159
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival.
Conway C; Mitra A; Jewell R; Randerson-Moor J; Lobo S; Nsengimana J; Edward S; Sanders DS; Cook M; Powell B; Boon A; Elliott F; de Kort F; Knowles MA; Bishop DT; Newton-Bishop J
Clin Cancer Res; 2009 Nov; 15(22):6939-46. PubMed ID: 19887478
[TBL] [Abstract][Full Text] [Related]
9. Osteopontin expression in plasma of melanoma patients and in melanocytic tumours.
Maier T; Laubender RP; Sturm RA; Klingenstein A; Korting HC; Ruzicka T; Berking C
J Eur Acad Dermatol Venereol; 2012 Sep; 26(9):1084-91. PubMed ID: 21838826
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase III trial.
Lim AM; Rischin D; Fisher R; Cao H; Kwok K; Truong D; McArthur GA; Young RJ; Giaccia A; Peters L; Le QT
Clin Cancer Res; 2012 Jan; 18(1):301-7. PubMed ID: 22096023
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of serum osteopontin level and gene polymorphism as biomarkers: analyses from the Nordic Adjuvant Interferon alpha Melanoma trial.
Prasmickaite L; Berge G; Bettum IJ; Aamdal S; Hansson J; Bastholt L; Øijordsbakken M; Boye K; Mælandsmo GM
Cancer Immunol Immunother; 2015 Jun; 64(6):769-76. PubMed ID: 25832001
[TBL] [Abstract][Full Text] [Related]
12. Plasma markers for identifying patients with metastatic melanoma.
Kluger HM; Hoyt K; Bacchiocchi A; Mayer T; Kirsch J; Kluger Y; Sznol M; Ariyan S; Molinaro A; Halaban R
Clin Cancer Res; 2011 Apr; 17(8):2417-25. PubMed ID: 21487066
[TBL] [Abstract][Full Text] [Related]
13. Melanoma inhibitory activity (MIA), a serological marker of malignant melanoma.
Bosserhoff AK; Dreau D; Hein R; Landthaler M; Holder WD; Buettner R
Recent Results Cancer Res; 2001; 158():158-68. PubMed ID: 11092043
[TBL] [Abstract][Full Text] [Related]
14. Osteopontin and 'melanoma inhibitory activity': comparison of two serological tumor markers in metastatic uveal melanoma patients.
Haritoglou I; Wolf A; Maier T; Haritoglou C; Hein R; Schaller UC
Ophthalmologica; 2009; 223(4):239-43. PubMed ID: 19270465
[TBL] [Abstract][Full Text] [Related]
15. VEGF-165 serum levels and tyrosinase expression in melanoma patients: correlation with the clinical course.
Osella-Abate S; Quaglino P; Savoia P; Leporati C; Comessatti A; Bernengo MG
Melanoma Res; 2002 Aug; 12(4):325-34. PubMed ID: 12170181
[TBL] [Abstract][Full Text] [Related]
16. Osteopontin as a serologic marker for metastatic uveal melanoma: results of a pilot study.
Reiniger IW; Wolf A; Welge-Lüssen U; Mueller AJ; Kampik A; Schaller UC
Am J Ophthalmol; 2007 Apr; 143(4):705-7. PubMed ID: 17386288
[TBL] [Abstract][Full Text] [Related]
17. Significance of plasma cytokine levels in melanoma patients with histologically negative sentinel lymph nodes.
Porter GA; Abdalla J; Lu M; Smith S; Montgomery D; Grimm E; Ross MI; Mansfield PF; Gershenwald JE; Lee JE
Ann Surg Oncol; 2001 Mar; 8(2):116-22. PubMed ID: 11258775
[TBL] [Abstract][Full Text] [Related]
18. Fas and Fas ligand: expression and soluble circulating levels in cutaneous malignant melanoma.
Redondo P; Solano T; VAzquez B; Bauza A; Idoate M
Br J Dermatol; 2002 Jul; 147(1):80-6. PubMed ID: 12100188
[TBL] [Abstract][Full Text] [Related]
19. The role of osteopontin expression in melanoma progression.
Kiss T; Ecsedi S; Vizkeleti L; Koroknai V; Emri G; Kovács N; Adany R; Balazs M
Tumour Biol; 2015 Sep; 36(10):7841-7. PubMed ID: 25944164
[TBL] [Abstract][Full Text] [Related]
20. OPG, OPN, EGF and VEGF Levels at Individual Breslow Score Stages in Malignant Melanoma.
Treskova I; Topolcan O; Windrichova J; Simanek V; Slouka D; Treska V; Kucera R
Anticancer Res; 2018 Aug; 38(8):4907-4911. PubMed ID: 30061268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
